ABSTRACT
Beta 2 glycoprotein I (ß2GPI) is the major autoantigen in the antiphospholipid syndrome, an autoimmune disorder characterized by thrombotic and obstetric complications. The autoantibodies that target beta 2 glycoprotein I are pathogenic and contribute to disease pathogenesis. The ß2GPI molecule is composed of 5 domains that are numbered 1 through to 5. Autoantibodies bind mainly to domain 1 whereas the majority of the biological functions of the ß2GPI molecule in diverse processes such as apoptotic cell clearance, complement regulation, lipopolysaccharide clearance and anticoagulation have been localised to domain 5 and its unique biochemistry, reviewed in this article. The role of purified domain 5 peptide as a potential therapeutic agent in APS and ischemia reperfusion injury is discussed.
Subject(s)
Antiphospholipid Syndrome , Autoantibodies , beta 2-Glycoprotein I , Humans , beta 2-Glycoprotein I/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/drug therapy , Autoantibodies/immunology , Protein Domains , Animals , Autoantigens/immunology , Reperfusion Injury/immunologyABSTRACT
Little is known about the physiological role of beta-2-glycoprotein I (ß2GPI) despite it being the major auto-antigen in the antiphospholipid syndrome. A systematic study of the role of ß2GPI in thrombus formation in vivo has not been performed to date. Herein, we report that ß2GPI deficient (-/-) mice have enhanced thrombus formation compared to wild type (WT) mice in a laser-induced arteriole and venule model of thrombosis. Furthermore, neutrophil accumulation and elastase activity was enhanced in thrombi of ß2GPI -/- compared with WT mice. The antithrombotic function of ß2GPI is dependent on its fifth domain (domain V); intravenous administration of the ß2GPI domain deletion mutant lacking domain V (human recombinant domain I-IV) had no effect on platelet and fibrin thrombus size in ß2GPI -/- or WT mice. On the contrary, intravenous administration of human recombinant domain V significantly inhibited platelet and fibrin thrombus size in both ß2GPI -/- mice and WT mice. These findings reveal a major role for ß2GPI as a natural anticoagulant and implicate domain V of ß2GPI as a potential antithrombotic therapy.
Subject(s)
Antiphospholipid Syndrome , Thrombosis , beta 2-Glycoprotein I , Animals , Anticoagulants , Antiphospholipid Syndrome/drug therapy , Antiphospholipid Syndrome/genetics , Fibrinolytic Agents , Mice , Mice, Knockout , beta 2-Glycoprotein I/physiologyABSTRACT
OBJECTIVE: Atherosclerotic coronary artery disease is well recognised as an inflammatory disorder that is also influenced by oxidative stress. ß2-GPI (ß-2-glycoprotein-I) is a circulating plasma protein that undergoes post-translational modification and exists in free thiol as well as oxidized forms. The aim of this study was to assess the association between these 2 post-translational redox forms of ß2-GPI and atherosclerotic coronary artery disease. Approach and Results: Stable patients presenting for elective coronary angiography or CT coronary angiography were prospectively recruited. A separate group of patients after reperfused ST-segment-elevation myocardial infarction formed an acute coronary syndrome subgroup. All patients had collection of fasting serum and plasma for quantification of total and free thiol ß2-GPI. Coronary artery disease extent was quantified by the Syntax and Gensini scores. A total of 552 patients with stable disease and 44 with acute coronary syndrome were recruited. While total ß2-GPI was not associated with stable coronary artery disease, a higher free thiol ß2-GPI was associated with its presence and extent. This finding remained significant after correcting for confounding variables, and free thiol ß2-GPI was a better predictor of stable coronary artery disease than hs-CRP (high-sensitivity C-reactive protein). Paradoxically, there were lower levels of free thiol ß2-GPI after ST-segment-elevation myocardial infarction. CONCLUSIONS: Free thiol ß2-GPI is a predictor of coronary artery disease presence and extent in stable patients. Free thiol ß2-GPI was a better predictor than high-sensitivity C-reactive protein.
Subject(s)
Coronary Artery Disease/blood , Inflammation/blood , Oxidative Stress , beta 2-Glycoprotein I/blood , Acute Coronary Syndrome/blood , Acute Coronary Syndrome/diagnostic imaging , Aged , Biomarkers/blood , C-Reactive Protein/analysis , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Female , Heart Disease Risk Factors , Humans , Inflammation/diagnosis , Inflammation Mediators/blood , Lipids/blood , Male , Middle Aged , Oxidation-Reduction , Predictive Value of Tests , Prospective Studies , ST Elevation Myocardial Infarction/blood , ST Elevation Myocardial Infarction/diagnostic imagingABSTRACT
Complement Factor H (CFH) is an important inhibitor of the alternate complement pathway in Bruch's membrane (BM), located between the choriocapillaris and the retinal pigment epithelium. Furthermore dysfunction of its activity as occurs with certain polymorphisms is associated with an increased risk of age related macular degeneration (AMD). The retina is a site of high generation of reactive oxygen species (ROS) and dysfunction of redox homeostasis in this milieu also contributes to AMD pathogenesis. In this study we wanted to explore if CFH exists in distinct redox forms and whether these species have unique protective biological functions. CFH can be reduced by the naturally occurring thioredoxin -â¯1 in CFH domains 1-4, 17-20. We found a duality of function between the oxidised and reduced forms of CFH. The oxidised form was more efficient in binding to C3b and lipid peroxidation by-products that are known to accumulate in the retinae and activate the alternate complement pathway. Oxidised CFH enhances Factor I mediated cleavage of C3 and C3b whereas the reduced form loses this activity. In the setting of oxidative stress (hydrogen peroxide)-mediated death of human retinal pigment epithelial cells as can occur in AMD, the free thiol form of CFH offers a protective function compared to the oxidised form. We found for the first time using a novel ELISA system we have developed for free thiol CFH, that both redox forms of CFH are found in the human plasma. Furthermore there is a distinct ratio of these redox forms in plasma depending if an individual has early or late AMD, with individuals with early AMD having higher levels of the free thiol form compared to late AMD.
Subject(s)
Complement C3b/metabolism , Complement Factor I/metabolism , Macular Degeneration/genetics , Reactive Oxygen Species/metabolism , Aged , Bruch Membrane/immunology , Bruch Membrane/pathology , Case-Control Studies , Cell Line , Complement Activation/genetics , Complement C3b/genetics , Complement Factor H/genetics , Complement Factor H/metabolism , Complement Factor I/genetics , Complement Pathway, Alternative/genetics , Epithelial Cells/cytology , Epithelial Cells/immunology , Female , Gene Expression , Humans , Lipid Peroxidation , Macular Degeneration/immunology , Macular Degeneration/pathology , Male , Oxidation-Reduction , Protein Binding , Proteolysis , Reactive Oxygen Species/immunology , Retinal Pigment Epithelium/immunology , Retinal Pigment Epithelium/pathology , Time FactorsABSTRACT
The anti-phospholipid syndrome (APS) is a prothrombotic autoimmune disorder characterized by either thrombosis or pregnancy complications in the setting of persistent anti-phospholipid antibodies (aPL). ßeta 2-glycoprotein I (ß2-GPI) is the major autoantigen in APS that binds anionic phospholipids as well as specific receptors on platelets and endothelial cells resulting in activation of prothrombotic pathways. ß2-GPI consists of 5 Domains that exist in a circular or linear form, with the latter occurring after binding to anionic phospholipids. ß2-GPI also undergoes dynamic posttranslational modification between oxidized and free thiol forms. The relationship between posttranslational modification and structural conformation is yet to be definitively clarified. Compared with controls, patients with the APS have higher levels of total ß2-GPI and lower levels of free thiol ß2-GPI. This raises the possibility of using quantification of ß2-GPI posttranslational modification as a redox biomarker in the management and diagnosis of the APS.
Subject(s)
Antiphospholipid Syndrome/physiopathology , Oxidative Stress , Protein Processing, Post-Translational , beta 2-Glycoprotein I/chemistry , beta 2-Glycoprotein I/metabolism , Animals , Glycolysis , Humans , Oxidation-ReductionABSTRACT
The constitutive heparin+ (HP) mast cells (MCs) in mice express mouse MC protease (mMCP)-5 and carboxypeptidase A (mMC-CPA). The amino acid sequence of mMCP-5 is most similar to that of human chymase-1, as are the nucleotide sequences of their genes and transcripts. Using a homologous recombination approach, a C57BL/6 mouse line was created that possessed a disrupted mMCP-5 gene. The resulting mice were fertile and had no obvious developmental abnormality. Lack of mMCP-5 protein did not alter the granulation of the IL-3/IL-9-dependent mMCP-2+ MCs in the jejunal mucosa of Trichinella spiralis-infected mice. In contrast, the constitutive HP+ MCs in the tongues of mMCP-5-null mice were poorly granulated and lacked mMC-CPA protein. Bone marrow-derived MCs were readily developed from the transgenic mice using IL-3. Although these MCs contained high levels of mMC-CPA mRNA, they also lacked the latter exopeptidase. mMCP-5 protein is therefore needed to target translated mMC-CPA to the secretory granule along with HP-containing serglycin proteoglycans. Alternately, mMCP-5 is needed to protect mMC-CPA from autolysis in the cell's granules. Fibronectin was identified as a target of mMCP-5, and the exocytosis of mMCP-5 from the MCs in the mouse's peritoneal cavity resulted in the expression of metalloproteinase protease-9, which has been implicated in arthritis. In support of the latter finding, experimental arthritis was markedly reduced in mMCP-5-null mice relative to wild-type mice in two disease models.
Subject(s)
Arthritis, Experimental/pathology , Chymases/adverse effects , Mast Cells/enzymology , Animals , Arthritis, Experimental/enzymology , Arthritis, Experimental/etiology , Carboxypeptidases A/analysis , Carboxypeptidases A/deficiency , Carboxypeptidases A/metabolism , Chymases/deficiency , Chymases/physiology , Humans , Mast Cells/metabolism , Mast Cells/pathology , Mice , Mice, Inbred C57BL , Secretory Vesicles/metabolismABSTRACT
Nitrosative stress has been implicated in the pathogenesis of age related macular degeneration (AMD). Tyrosine nitration is a unique type of post translational modification that occurs in the setting of inflammation and nitrosative stress. To date, the significance and functional implications of tyrosine nitration of complement factor H (CFH), a key complement regulator in the eye has not been explored, and is examined in this study in the context of AMD pathogenesis.Sections of eyes from deceased individuals with AMD (n = 5) demonstrated the presence of immunoreactive nitrotyrosine CFH. We purified nitrated CFH from retinae from 2 AMD patients. Mass spectrometry of CFH isolated from AMD eyes revealed nitrated residues in domains critical for binding to heparan sulphate glycosaminoglycans (GAGs), lipid peroxidation by-products and complement (C) 3b.Functional studies revealed that nitrated CFH did not bind to lipid peroxidation products, nor to the GAG of perlecan nor to C3b. There was loss of cofactor activity for Factor I mediated cleavage of C3b with nitrated CFH compared to non-nitrated CFH. CFH inhibits, but nitrated CFH significantly potentiates, the secretion of the pro-inflammatory and angiogenic cytokine IL-8 from monocytes that have been stimulated with lipid peroxidation by-products. AMD patients (n = 30) and controls (n = 30) were used to measure plasma nitrated CFH using a novel ELISA. AMD patients had significantly elevated nitrated CFH levels compared to controls (p = 0.0117). These findings strongly suggest that nitrated CFH contributes to AMD progression, and is a target for therapeutic intervention.
Subject(s)
Complement Factor H/metabolism , Disease Susceptibility , Immunomodulation , Macular Degeneration/etiology , Macular Degeneration/metabolism , Tyrosine/genetics , Aged , Aged, 80 and over , Amino Acid Sequence , Biomarkers , Case-Control Studies , Choroid/immunology , Choroid/metabolism , Choroid/pathology , Complement C3b/immunology , Complement C3b/metabolism , Complement Factor H/chemistry , Enzyme-Linked Immunosorbent Assay , Female , Heparan Sulfate Proteoglycans/metabolism , Humans , Macular Degeneration/diagnosis , Male , Monocytes/immunology , Monocytes/metabolism , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Binding , Protein Transport , Proteolysis , Reactive Nitrogen Species/metabolism , Retina/immunology , Retina/metabolism , Retina/pathology , Severity of Illness Index , Tandem Mass SpectrometryABSTRACT
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understanding of the underlying complex pathogenesis of the APS. The first was the discovery that beta-2 glycoprotein-1 (ß2GPI) is the major auto antigen in APS. The second was the discovery in more recent years that ß2GPI contains allosteric disulphide bonds susceptible to posttranslational modification that may be involved in the development of autoantibodies in APS. The main allosteric disulphide bond in the fifth domain of ß2GPI can exist in two redox states: free thiol or oxidised. It is the conformational transformation of ß2GPI from its free thiol form to its more immunogenic oxidised form that exposes neo-epitopes on the first and fifth domains. The purpose of this review is to highlight the recent findings on the posttranslational forms of ß2GPI in the pathogenesis of APS. We suggest that novel assays quantitating the different redox forms of ß2GPI in plasma or serum may be used to supplement existing clinical and laboratory assays to more accurately stratify risk of thrombosis or miscarriage in APS patients.
ABSTRACT
Lipopolysaccharide (LPS) is a major component of the outer wall of gram negative bacteria. In high doses LPS contributes to the inflammation in gram negative sepsis, and in low doses contributes to the low grade inflammation characteristic of the metabolic syndrome. We wanted to assess the role of beta2-glycoprotein I (ß2GPI) a highly conserved plasma protein and its different biochemical forms in a mouse model of LPS systemic inflammation. Normal and ß2GPI deficient mice were administered LPS through their veins and assessed for a range of inflammation markers in their blood and liver. Different biochemical forms of ß2GPI were measured in normal mice given either saline or LPS. We show that ß2GPI has a significant role in inhibiting LPS induced inflammation. In this study we provide some evidence that ß2GPI serves a protective role in a mouse model of LPS inflammation. This resolves the controversy of previous studies which used LPS and ß2GPI in test tube based models of LPS induced activation of white cells. We also highlight the potential relevance of a newly discovered biochemical form of ß2GPI in LPS mediated inflammation and we speculate that this form has a protective role against LPS induced pathology.
ABSTRACT
Reperfusion after a period of ischemia results in reperfusion injury (IRI) which involves activation of the inflammatory cascade. In cardiac IRI, IgM natural antibodies (NAb) play a prominent role through binding to altered neoepitopes expressed on damaged cells. Beta 2 Glycoprotein I (ß2GPI) is a plasma protein that binds to neoepitopes on damaged cells including anionic phospholipids through its highly conserved Domain V. Domain I of ß2GPI binds circulating IgM NAbs and may provide a link between the innate immune system, IgM NAb binding and cardiac IRI. This study was undertaken to investigate the role of Β2GPI and its Domain V in cardiac IRI using wild-type (WT), Rag-1 -/- and ß2GPI deficient mice. Compared with control, treatment with Domain V prior to cardiac IRI prevented binding of endogenous ß2GPI to post-ischemic myocardium and resulted in smaller myocardial infarction size in both WT and ß2GPI deficient mice. Domain V treatment in WT mice also resulted in less neutrophil infiltration, less apoptosis and improved ejection fraction at 24 h. Rag-1 -/- antibody deficient mice reconstituted with IgM NAbs confirmed that Domain V prevented IgM NAb induced cardiac IRI. Domain V remained equally effective when delivered at the time of reperfusion which has therapeutic clinical relevance.Based upon this study Domain V may function as a universal inhibitor of IgM NAb binding in the setting of cardiac IRI, which offers promise as a new therapeutic strategy in the treatment of cardiac IRI.
Subject(s)
Immunity, Innate/drug effects , Immunoglobulin M/immunology , Myocardial Reperfusion Injury/prevention & control , beta 2-Glycoprotein I/pharmacology , Animals , Immunity, Innate/genetics , Mice , Mice, Knockout , Myocardial Reperfusion Injury/genetics , Myocardial Reperfusion Injury/immunology , Myocardial Reperfusion Injury/pathology , Protein Structure, Tertiary , beta 2-Glycoprotein I/genetics , beta 2-Glycoprotein I/immunologyABSTRACT
Ras guanine nucleotide-releasing protein-4 (RasGRP4) is an evolutionarily conserved calcium-regulated, guanine nucleotide exchange factor and diacylglycerol/phorbol ester receptor. While an important intracellular signaling protein for CD117+ mast cells (MCs), its roles in other immune cells is less clear. In this study, we identified a subset of in vivo-differentiated splenic CD117+ dendritic cells (DCs) in wild-type (WT) C57BL/6 mice that unexpectedly contained RasGRP4 mRNA and protein. In regard to the biologic significance of these data to innate immunity, LPS-treated splenic CD117+ DCs from WT mice induced natural killer (NK) cells to produce much more interferon-γ (IFN-γ) than comparable DCs from RasGRP4-null mice. The ability of LPS-responsive MCs to cause NK cells to increase their expression of IFN-γ was also dependent on this intracellular signaling protein. The discovery that RasGRP4 is required for CD117+ MCs and DCs to optimally induce acute NK cell-dependent immune responses to LPS helps explain why this signaling protein has been conserved in evolution.
Subject(s)
Dendritic Cells/immunology , Killer Cells, Natural/immunology , Lipopolysaccharides/pharmacology , Mast Cells/immunology , Proto-Oncogene Proteins c-kit/immunology , ras Guanine Nucleotide Exchange Factors/physiology , Animals , Coculture Techniques , Interferon-gamma/metabolism , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , OX40 Ligand , Signal Transduction , Spleen/cytology , Spleen/drug effects , Spleen/immunology , Tumor Necrosis Factors/metabolismABSTRACT
Age-related macular degeneration (AMD) affects the region of the retina that is responsible for high-resolution vision. It is a major cause of blindness in the aging population. This is the first study that examines the association of redox-modified, cysteine-based, post-translational forms of beta 2-glycoprotein I (ß2GPI) in the plasma of individuals with early and late stages of patients with AMD compared with controls. Exploration is also undertaken to assess whether the free thiol form of ß2GPI versus the oxidized disulfide form have distinct functional properties in the setting of hydrogen peroxide (H(2)O(2))-mediated cell death of an immortalized human retinal pigment epithelium (RPE) cell line. We demonstrate ß2GPI in the retina and choroid of patients with AMD. Free thiol ß2GPI is shown to protect the immortalized human RPE cell line against H(2)O(2)-induced cell death, whereas the oxidized form of ß2GPI and free thiol bovine serum albumin were not protective. Free thiol ß2GPI levels were significantly decreased in patients with late AMD compared with early AMD and healthy controls. Our observations lead to the hypothesis that free thiol ß2GPI may protect against oxidative stress injury to RPE cells in the early stages of AMD.
Subject(s)
Disulfides/metabolism , Macular Degeneration/metabolism , Macular Degeneration/physiopathology , Retina/metabolism , beta 2-Glycoprotein I/metabolism , beta 2-Glycoprotein I/pharmacology , Animals , Cattle , Cell Death/drug effects , Cell Line , Humans , Hydrogen Peroxide/pharmacology , Serum Albumin, Bovine/pharmacologyABSTRACT
OBJECTIVE: Angiotensinogen exists in two distinct redox forms in plasma, the oxidized sulfhydryl-bridge form and the reduced, unbridged, free thiol form. The oxidized form of angiotensinogen compared to the free thiol form preferentially interacts with renin resulting in increased generation of angiotensin. The predictive potential of the ratio of free-thiol to oxidized angiotensinogen in the plasma for pre-eclampsia was first suggested by the Read group in ref 10. We propose an improved method for determining the ratio and validate the method in a larger cohort of pregnant women. METHODS: Plasma samples from 115 individuals with pre-eclampsia and from 55 healthy pregnant control subjects were collected sequentially over a 2 year period. Using two distinct enzyme-linked immunosorbent assays (ELISAs) the plasma levels of total and free thiol angiotensinogen were quantified. The oxidized angiotensinogen plasma level is derived by subtracting the level of free thiol, reduced angiotensinogen from the total angiotensinogen levels in the plasma. RESULTS: The relative proportion of free thiol angiotensinogen, expressed as a percentage of that observed with an in-house standard, is significantly decreased in pre-eclamptic patients (70.85% ± 29.49%) (mean ± SD) as compared to healthy pregnant controls (92.98 ± 24.93%) (mean ± SD) p ≤ 0.0001. The levels of total angiotensinogen did not differ between the two groups. CONCLUSION: Patients with pre-eclampsia had substantially lower levels of free thiol angiotensinogen compared to healthy pregnant controls, whilst maintaining similar total angiotensinogen levels in the plasma. Hence, elevated levels of plasma oxidized angiotensinogen may be a contributing factor to hypertension in the setting of pre-eclampsia.
Subject(s)
Angiotensinogen/blood , Angiotensinogen/chemistry , Biological Assay/methods , Biomarkers/blood , Pre-Eclampsia/diagnosis , Adult , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Oxidation-Reduction , Oxidative Stress , Pre-Eclampsia/blood , Pregnancy , ROC CurveABSTRACT
Protease serine member S31 (Prss31)/transmembrane tryptase/tryptase-γ is a mast cell (MC)-restricted protease of unknown function that is retained on the outer leaflet of the plasma membrane when MCs are activated. We determined the nucleotide sequences of the Prss31 gene in different mouse strains and then used a Cre/loxP homologous recombination approach to create a novel Prss31(-/-) C57BL/6 mouse line. The resulting animals exhibited no obvious developmental abnormality, contained normal numbers of granulated MCs in their tissues, and did not compensate for their loss of the membrane tryptase by increasing their expression of other granule proteases. When Prss31-null MCs were activated with a calcium ionophore or by their high affinity IgE receptors, they degranulated in a pattern similar to that of WT MCs. Prss31-null mice had increased baseline airway reactivity to methacholine but markedly reduced experimental chronic obstructive pulmonary disease and colitis, thereby indicating both beneficial and adverse functional roles for the tryptase. In a cigarette smoke-induced model of chronic obstructive pulmonary disease, WT mice had more pulmonary macrophages, higher histopathology scores, and more fibrosis in their small airways than similarly treated Prss31-null mice. In a dextran sodium sulfate-induced acute colitis model, WT mice lost more weight, had higher histopathology scores, and contained more Cxcl-2 and IL-6 mRNA in their colons than similarly treated Prss31-null mice. The accumulated data raise the possibility that inhibitors of this membrane tryptase may provide additional therapeutic benefit in the treatment of humans with these MC-dependent inflammatory diseases.
Subject(s)
Colitis/enzymology , Lung/physiopathology , Mast Cells/enzymology , Membrane Proteins/immunology , Pulmonary Disease, Chronic Obstructive/enzymology , Tryptases/immunology , Animals , Colitis/genetics , Colitis/immunology , Colitis/physiopathology , Disease Models, Animal , Humans , Lung/enzymology , Lung/immunology , Male , Mast Cells/immunology , Membrane Proteins/genetics , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Knockout , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Disease, Chronic Obstructive/physiopathology , Tryptases/geneticsABSTRACT
OBJECTIVE: The BXSB.Yaa mouse strain is a model of systemic lupus erythematosus that is dependent on duplication of the Toll-like receptor 7 gene. The objective of this study was to systematically describe the amplified autoimmune phenotype observed when the soluble plasma protein ß2 -glycoprotein I (ß2 GPI) gene was deleted in male BXSB.Yaa mice. METHODS: We generated BXSB.Yaa and NZW mouse strains in which the ß2 GPI gene had been knocked out by backcrossing the wild-type strains with C57BL/6 ß2 GPI(-/-) mice for 10 generations. Sex- and age-matched mice of the various strains were housed under identical conditions and were killed at fixed time intervals. Serum and tissue specimens were collected at various time points. Lupus-associated autoantibodies, inflammatory cytokines, and the type I interferon (IFN) gene signature were measured. Flow cytometric analyses of lymphocyte populations were performed. The severity of glomerulonephritis was graded by 2 independent renal histopathologists. RESULTS: Male BXSB.Yaa ß2 GPI(-/-) mice developed significant lymphadenopathy and splenomegaly compared with age-matched controls. Male BXSB.Yaa ß2 GPI(-/-) mice also had significantly higher levels of autoantibodies, increased levels of inflammatory cytokines including tumor necrosis factor α, interleukin-6, and BAFF, and more severe glomerulonephritis. The type I IFN gene signature in male BXSB.Yaa ß2 GPI(-/-) mice was significantly higher than that in control mice. Male BXSB.Yaa ß2 GPI(-/-) mice also had marked dysregulation of various B cell and T cell populations in the spleens and lymph nodes and a disturbance in apoptotic cell clearance. CONCLUSION: Deletion of ß2 GPI accelerates and potentiates the autoimmune phenotype in male BXSB.Yaa mice.
Subject(s)
Lupus Erythematosus, Systemic/genetics , Lupus Erythematosus, Systemic/immunology , beta 2-Glycoprotein I/genetics , Animals , Antiphospholipid Syndrome/immunology , Autoantigens/immunology , Disease Models, Animal , Gene Deletion , Male , Membrane Glycoproteins/physiology , Mice , Mice, Inbred C57BL , Phenotype , Toll-Like Receptor 7/physiology , beta 2-Glycoprotein I/immunologyABSTRACT
Mast cells (MCs) are active participants in blood coagulation and innate and acquired immunity. This review focuses on the development of mouse and human MCs, as well as the involvement of their granule serine proteases in inflammation and the connective tissue remodeling that occurs during the different phases of the healing process of wounded skin and other organs. The accumulated data suggest that MCs, their tryptases, and their chymases play important roles in tissue repair. While MCs initially promote healing, they can be detrimental if they are chronically stimulated or if too many MCs become activated at the same time. The possibility that MCs and their granule serine proteases contribute to the formation of keloid and hypertrophic scars makes them potential targets for therapeutic intervention in the repair of damaged skin.
Subject(s)
Cell Differentiation/immunology , Inflammation/enzymology , Inflammation/immunology , Mast Cells/enzymology , Mast Cells/immunology , Tryptases/physiology , Wound Healing/immunology , Animals , Bone Marrow Cells/enzymology , Bone Marrow Cells/immunology , Fetus , Humans , Inflammation/pathology , Liver/cytology , Liver/enzymology , Liver/immunology , Mast Cells/pathology , MiceABSTRACT
This chapter reviews several important themes pertaining to the antiphospholipid syndrome (APS), including a description of the clinical features, a discussion of the main autoantigen, beta 2-glycoprotein I (ß2GPI), and insights into the characteristics of the pathogenic anti-ß2GPI autoantibodies. Evidence-based considerations for when to test for APS are explored, along with the clinical significance of patients testing positive on multiple APS assays, so-called triple positivity. A detailed review of recently published laboratory guidelines for the detection of lupus anticoagulant and the solid-phase anticardiolipin and anti-ß2GPI ELISAs is undertaken. Finally, a brief review of nonclassification criteria laboratory assays with potential future diagnostic utility is presented.
Subject(s)
Antibodies, Antiphospholipid/analysis , Clinical Laboratory Techniques/methods , Antiphospholipid Syndrome/diagnosis , Autoantibodies/immunology , Humans , Lupus Coagulation Inhibitor/analysis , beta 2-Glycoprotein I/metabolismSubject(s)
Antiphospholipid Syndrome/etiology , Lupus Coagulation Inhibitor/physiology , Animals , Antiphospholipid Syndrome/physiopathology , Disease Models, Animal , Factor XI/physiology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Immunity, Innate/physiology , Mice , Oxidation-Reduction , Thromboplastin/physiology , Thrombosis/etiology , beta 2-Glycoprotein I/metabolismABSTRACT
Factor XI (FXI), a disulfide-linked covalent homodimer, circulates in plasma, and upon activation initiates the intrinsic/consolidation phase of coagulation. We present evidence that disulfide bonds in FXI are reduced to free thiols by oxidoreductases thioredoxin-1 (TRX-1) and protein disulfide isomerase (PDI). We identified that Cys362-Cys482 and Cys118-Cys147 disulfide bonds are reduced by TRX-1. The activation of TRX-1-treated FXI by thrombin, FXIIa or FXIa was significantly increased compared to non-reduced FXI, indicating that the reduced factor is more efficiently activated than the oxidized protein. Using a novel ELISA system, we compared the amount of reduced FXI in antiphospholipid syndrome (APS) thrombosis patients with levels in healthy controls, and found that APS patients have higher levels of reduced FXI. This may have implication for understanding the contribution of FXI to APS thrombosis, and the predisposition to thrombosis in patients with elevated plasma levels of reduced FXI.
Subject(s)
Antiphospholipid Syndrome/blood , Factor XI/agonists , Protein Disulfide-Isomerases/blood , Thioredoxins/blood , Thrombosis/blood , Adult , Aged , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/enzymology , Blood Coagulation , Case-Control Studies , Cysteine/metabolism , Disulfides/chemistry , Enzyme-Linked Immunosorbent Assay , Factor XI/chemistry , Factor XI/metabolism , Factor XIIa/metabolism , Factor XIIa/pharmacology , Factor XIa/metabolism , Factor XIa/pharmacology , Female , Humans , Male , Middle Aged , Oxidation-Reduction , Thioredoxins/metabolism , Thioredoxins/pharmacology , Thrombin/metabolism , Thrombin/pharmacology , Thrombosis/complications , Thrombosis/enzymologyABSTRACT
RasGRP4 (Ras guanine nucleotide-releasing protein-4) is an intracellular, calcium-regulated guanine nucleotide exchange factor and diacylglycerol/phorbol ester receptor expressed in mast cells (MCs) and their progenitors. To study the function of this signaling protein in inflammatory disorders, a homologous recombination approach was used to create a RasGRP4-null C57BL/6 mouse line. The resulting transgenic animals had normal numbers of MCs in their tissues that histochemically and morphologically resembled those in WT C57BL/6 mice. MCs could also be generated from RasGRP4-null mice by culturing their bone marrow cells in IL-3-enriched conditioned medium. Despite these data, the levels of the transcripts that encode the proinflammatory cytokines IL-1ß and TNF-α were reduced in phorbol 12-myristate 13-acetate-treated MCs developed from RasGRP4-null mice. Although inflammation was not diminished in a Dermatophagoides farinae-dependent model of allergic airway disease, dextran sodium sulfate-induced colitis was significantly reduced in RasGRP4-null mice relative to similarly treated WT mice. Furthermore, experimental arthritis could not be induced in RasGRP4-null mice that had received K/BxN mouse serum. The latter findings raise the possibility that the pharmacologic inactivation of this intracellular signaling protein might be an effective treatment for arthritis or inflammatory bowel disease.